Meeting
2021 ASCO Annual Meeting
Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from POLARIS.
Authors
Gabrielle Betty Rocque
University of Alabama at Birmingham, Birmingham, AL
Gabrielle Betty Rocque , Joanne Lorraine Blum , Aldemar Montero , Meghan Sri Karuturi , Kenneth Manning , Lloyd Shabazz , Christopher Gallagher , Lara Zuberi , Joseph C Cappelleri , Marc Drucker , Yao Wang , Debu Tripathy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03280303
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1071)
DOI
10.1200/JCO.2021.39.15_suppl.1071
Abstract #
1071
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
Poster
2019 ASCO Quality Care Symposium
Understanding palbociclib practice patterns in a real-world setting.
First Author: Gabrielle Betty Rocque
Poster
2022 ASCO Annual Meeting
Aromatase inhibitors for breast cancer therapy: Analysis of real-world FAERS data.
First Author: Dawood Findakly
Poster
2019 ASCO Annual Meeting
Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET).
First Author: Cynthia Huang Bartlett